Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition.

Area of Science:

• Biochemistry and Molecular Biology
• Enzymology
• Cancer Therapeutics

Background:

• Ribonucleotide reductase (RNR) is essential for producing deoxyribonucleotide triphosphates (dNTPs), the building blocks for DNA.
• Eukaryotic RNR, composed of α and β subunits, utilizes radical chemistry initiated by a diferric-tyrosyl radical cofactor in the β subunit.
• Cellular regulation of RNR levels and activity is crucial for maintaining dNTP pools, ensuring DNA replication and repair fidelity.

Purpose of the Study:

• To review recent advancements in understanding eukaryotic RNR function and regulation.
• To highlight cellular mechanisms involved in RNR metallocofactor biosynthesis.
• To explore the implications of RNR regulation and cofactor biosynthesis in developing RNR-targeting therapeutics.

Main Methods:

• Literature review of recent studies on eukaryotic RNR.
• Analysis of research on RNR metallocofactor biosynthesis pathways.
• Synthesis of information on RNR's role in DNA metabolism and cancer therapy.

Main Results:

• Recent studies have elucidated complex cellular machineries governing RNR metallocofactor biosynthesis.
• Understanding these machineries provides insights into RNR's regulation and its susceptibility to therapeutic targeting.
• Dysregulation of RNR activity is linked to genomic instability and cancer development.

Conclusions:

• Eukaryotic RNR is a critical enzyme for DNA synthesis, tightly regulated by cellular mechanisms.
• The biosynthesis of RNR's radical cofactor is a key regulatory point with therapeutic relevance.
• Targeting RNR and its cofactor biosynthesis pathways offers promising strategies for cancer treatment.